Home  »  Trending   »  We Analyzed the Future Direction of Oramed Pharmac...

We Analyzed the Future Direction of Oramed Pharmaceuticals Inc. (ORMP), Here is What We Found

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) went down by -2.37% from its latest closing price compared to the recent 1-year high of $13.73. The company’s stock price has collected -18.90% of loss in the last five trading sessions.

Is It Worth Investing in Oramed Pharmaceuticals Inc. (NASDAQ :ORMP) Right Now?

Plus, the 36-month beta value for ORMP is at 2.08. Opinions of the stock are interesting as 1 analysts out of 4 who provided ratings for Oramed Pharmaceuticals Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 3 rated it as “hold,” and 0 as “sell.”

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


The average price from analysts is $18.75, which is $17.54 above the current price. ORMP currently public float of 37.06M and currently shorts hold a 7.61% ratio of that float. Today, the average trading volume of ORMP was 1.25M shares.

ORMP’s Market Performance

ORMP stocks went down by -18.90% for the week, with a monthly drop of -74.12% and a quarterly performance of -68.50%, while its annual performance rate touched -80.55%. The volatility ratio for the week stands at 14.18% while the volatility levels for the past 30 days are set at 13.53% for Oramed Pharmaceuticals Inc. The simple moving average for the period of the last 20 days is -76.65% for ORMP stocks with a simple moving average of -71.02% for the last 200 days.

Analysts’ Opinion of ORMP

Many brokerage firms have already submitted their reports for ORMP stocks, with Canaccord Genuity repeating the rating for ORMP by listing it as a “Hold.” The predicted price for ORMP in the upcoming period, according to Canaccord Genuity is $3 based on the research report published on January 12th of the current year 2023.

Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see ORMP reach a price target of $20. The rating they have provided for ORMP stocks is “Overweight” according to the report published on February 18th, 2022.

Canaccord Genuity gave a rating of “Buy” to ORMP, setting the target price at $27 in the report published on April 20th of the previous year.

ORMP Trading at -75.24% from the 50-Day Moving Average

After a stumble in the market that brought ORMP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -85.00% of loss for the given period.

Volatility was left at 13.53%, however, over the last 30 days, the volatility rate increased by 14.18%, as shares sank -75.12% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -69.35% lower at present.

During the last 5 trading sessions, ORMP fell by -18.90%, which changed the moving average for the period of 200-days by -77.11% in comparison to the 20-day moving average, which settled at $8.51. In addition, Oramed Pharmaceuticals Inc. saw -82.88% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at ORMP starting from Rabinowitz Michael, who sale 13,325 shares at the price of $12.55 back on Jan 03. After this action, Rabinowitz Michael now owns 126,143 shares of Oramed Pharmaceuticals Inc., valued at $167,195 using the latest closing price.

RAKIN KEVIN, the Director of Oramed Pharmaceuticals Inc., sale 10,000 shares at $9.41 during a trade that took place back on Mar 21, which means that RAKIN KEVIN is holding 46,661 shares at $94,096 based on the most recent closing price.

Stock Fundamentals for ORMP

Current profitability levels for the company are sitting at:

  • -857.68 for the present operating margin

The net margin for Oramed Pharmaceuticals Inc. stands at -822.72. Equity return is now at value -24.90, with -23.50 for asset returns.

The liquidity ratio also appears to be rather interesting for investors as it stands at 14.27.